NVCR NovoCure Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: NVCR

Price (delayed)

$15.69

Market cap

$1.83B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.3

Enterprise value

$1.96B

?
Relative Growth: Rel. Growth: 55
Relative Strength: Rel. Strength: 74
Relative Valuation: Rel. Valuation: 18
Relative Profitability: Rel. Profitability: 34
Highlights
The company's quick ratio has surged by 94% YoY
NovoCure's debt has plunged by 67% YoY
The equity has declined by 3.2% year-on-year but it has increased by 2.2% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Peers: NVAX NBIX

Key stats

What are the main financial stats of NVCR

NVCR stock price

How has the NovoCure stock price performed over time
Intraday
-2.24%
1 week
3.02%
1 month
-9.41%
1 year
37.75%
YTD
21.35%
QTD
3.56%

Financial performance

How have NovoCure's revenue and profit performed over time
Revenue
$699.19M
Gross profit
$532.27M
Operating income
-$154.4M
Net income
-$148.57M
Gross margin
76.1%
Net margin
-21.2%
NovoCure's net margin has increased by 22% YoY and by 18% from the previous quarter
NovoCure's operating margin has increased by 19% YoY and by 19% QoQ
NovoCure's operating income has increased by 16% QoQ and by 11% YoY
The net income has grown by 14% from the previous quarter and by 13% YoY

Price vs fundamentals

How does NVCR's price correlate with its fundamentals

Growth

What is NovoCure's growth rate over time

Valuation

What is NovoCure stock price valuation
NVCR P/E details
P/E
N/A
P/B
5.37
P/S
2.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.8
NVCR's EPS is up by 17% year-on-year and by 15% since the previous quarter
The price to book (P/B) is 48% lower than the 5-year quarterly average of 10.3 but 22% higher than the last 4 quarters average of 4.4
The equity has declined by 3.2% year-on-year but it has increased by 2.2% since the previous quarter
NVCR's price to sales (P/S) is 66% lower than its 5-year quarterly average of 7.6 but 18% higher than its last 4 quarters average of 2.2
The company's revenue rose by 11% YoY and by 3.7% QoQ

Efficiency

How efficient is NovoCure business performance
NVCR's return on sales is up by 19% year-on-year and by 19% since the previous quarter
NovoCure's ROIC has decreased by 15% YoY but it has increased by 7% from the previous quarter
The company's return on assets fell by 15% YoY but it rose by 3.6% QoQ
NovoCure's return on equity has increased by 13% QoQ and by 8% YoY

Dividends

What is NVCR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVCR.

Financial health

How did NovoCure financials performed over time
NovoCure's total assets is 74% more than its total liabilities
The company's current ratio has surged by 99% YoY
The company's quick ratio has surged by 94% YoY
NovoCure's debt is 31% less than its equity
NovoCure's debt has plunged by 67% YoY
NVCR's debt to equity has shrunk by 66% YoY and by 2.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.